Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials. The review did not find evidence to support cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
Behavioral therapy combined with stimulants is more effective and tolerable than other treatments for attention-deficit/hyperactivity disorder (ADHD), according to a recently published review and network meta-analysis of 190 randomized trials.
The researchers compared the efficacy and safety of medications, psychological and complementary and alternative medicine interventions for the treatment of ADHD in children and adolescents. The trials involved 26,114 participants.
Poor quality of care for pediatric ADHD care can lead to increased healthcare costs as adults, and this latest report, published in PLoS ONE, noted that many caregivers often turn to complementary and alternative medicine to try and control ADHD symptoms. The researchers noted that due to the lack of head-to-head trials, the comparative efficacy of drug and nondrug interventions is not known. However, this review found a lack of evidence for cognitive training, neurofeedback, antidepressants, antipsychotics, dietary therapy, fatty acids, and other complementary and alternative medicine.
They found that any intervention—behavioral therapy (alone or in combination with stimulants), stimulants, and non-stimulant—seemed significantly more effective than placebo. Other findings included:
While the medications were linked to some side effects (anorexia, weight loss and insomnia), an increased risk of serious adverse events was not observed.
The researchers noted that there is urgent need for high-quality randomized trials of the multiple treatments for ADHD in children and adolescents, and that before starting any treatment the risks and benefits need to be weighed.
Of their review, researchers wrote that their overall findings were limited by the clinical and methodological heterogeneity, small sample sizes of trials, short-term follow-up, and the absence of high-quality evidence.
Reference
Catalá-López F, Hutton B, Núñez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: a systematic review with network meta-analyses of randomised trials. PLoS One. 2017;12(7). doi.org/10.1371/journal.pone.0180355. Published July 12, 2017. Accessed December 18, 2017.
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More